Correction: Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2 (PLoS ONE (2014) 9, 6 (e101070) DOI: 10.1371/journal.pone.0101070);Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Hsieh, Tze Chen ^a   Lin, Chia Yi ^b   Bennett, Dylan John ^a   Wu, Erxi ^c   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; HISTIDINE; PLECKSTRIN; PROTEIN KINASE B; QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); RESVERATROL; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; CARRIER PROTEIN; NRH - QUINONE OXIDOREDUCTASE2; PROTEIN BINDING; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); STILBENE DERIVATIVE;

AFFINITY CHROMATOGRAPHY; AKT 1 GENE; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME METABOLISM; ENZYME REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR MODEL; NQO2 GENE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVATION; GENETICS; HYDROGEN BOND; METABOLISM; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN TRANSPORT; RNA STABILITY;

CARRIER PROTEINS; CELL LINE; ENZYME ACTIVATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; QUINONE REDUCTASES; RNA STABILITY; STILBENES;

EID: 84903388632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106137     Document Type: Erratum

References (45)

1. Chan TO, Tsichlis PN (2001) PDK2: a complex tail in one Akt. Sci STKE 2001: pe1.
2. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346 Pt 3: 561-576. (Pubitemid 30171014)
3. Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, et al. (1999) Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase-significance for diabetes and cancer. Pharmacol Ther 82: 409-425. (Pubitemid 29255934)
4. Brazil DP, Hemmings BA (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26: 657-664. (Pubitemid 33042488)
5. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245. (Pubitemid 29190320)
6. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501. (Pubitemid 37328931)
7. Di Cristofano A, Pandolfi PP (2000) The multiple roles of PTEN in tumor suppression. Cell 100: 387-390.
8. Blando J, Portis M, Benavides F, Alexander A, Mills G, et al. (2009) PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 174: 1869-1879.
9. Li R, Dai H, Wheeler TM, Sayeeduddin M, Scardino PT, et al. (2009) Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin Cancer Res 15: 3568-3573.
10. de Souza PL, Russell PJ, Kearsley J (2009) Role of the Akt pathway in prostate cancer. Curr Cancer Drug Targets 9: 163-175.
11. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
12. Ghosh PM (2012) What controls PTEN and what it controls (in prostate cancer). Asian J Androl 14: 130-131.
13. Benitez DA, Pozo-Guisado E, Clementi M, Castellon E, Fernandez-Salguero PM (2007) Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 96: 1595-1604. (Pubitemid 46762955)
14. Sexton E, Van Themsche C, LeBlanc K, Parent S, Lemoine P, et al. (2006) Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer 5: 45.
15. Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N (2006) Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 5: 1335-1341. (Pubitemid 43881327)
16. Hudson TS, Hartle DK, Hursting SD, Nunez NP, Wang TT, et al. (2007) Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res 67: 8396-8405. (Pubitemid 47395179)
17. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW (2007) Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 67: 1641-1653. (Pubitemid 350036950)
18. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, et al. (2004) Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43: 11417-11426. (Pubitemid 39186963)
19. Hsieh TC, Yang CJ, Lin CY, Lee YS, Wu JM (2012) Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells. Carcinogenesis 33: 670-677.
20. Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511. (Pubitemid 28553242)
21. Alt JR, Cleveland JL, Hannink M, Diehl JA (2000) Phosphorylation- dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114. (Pubitemid 32015129)
22. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063. (Pubitemid 350248462)
23. Winger JA, Hantschel O, Superti-Furga G, Kuriyan J (2009) The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol 9: 7.
24. Hsieh TC (2009) Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells. Asian J Androl 11: 653-661.
25. Hsieh TC (2009) Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 cells. Anticancer Res 29: 3011-3017.
26. Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM (2004) Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun 323: 743-749. (Pubitemid 39243382)
27. Hsieh TC, Wang Z, Deng H, Wu JM (2008) Identification of glutathione sulfotransferase-pi (GSTP1) as a new resveratrol targeting protein (RTP) and studies of resveratrol-responsive protein changes by resveratrol affinity chromatography. Anticancer Res 28: 29-36. (Pubitemid 351362877)
28. Wessel D, Flugge UI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138: 141-143. (Pubitemid 14146660)
29. Wang Z, Chen Y, Labinskyy N, Hsieh TC, Ungvari Z, et al. (2006) Regulation of proliferation and gene expression in cultured human aortic smooth muscle cells by resveratrol and standardized grape extracts. Biochem Biophys Res Commun 346: 367-376. (Pubitemid 43866007)
30. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
31. Tovchigrechko A, Vakser IA (2006) GRAMM-X public web server for protein-protein docking. Nucleic Acids Res 34: W310-314. (Pubitemid 44529784)
32. Tovchigrechko A, Vakser IA (2005) Development and testing of an automated approach to protein docking. Proteins 60: 296-301. (Pubitemid 40934902)
33. Sanner MF, Olson AJ, Spehner JC (1996) Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 38: 305-320.
34. Hsieh TC, Wong C, John Bennett D, Wu JM (2011) Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin alphavbeta3. Int J Cancer 129: 2732-2743.
35. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 33: W363-367. (Pubitemid 44529944)
36. Andrusier N, Nussinov R, Wolfson HJ (2007) FireDock: fast interaction refinement in molecular docking. Proteins 69: 139-159. (Pubitemid 47339146)
37. Mashiach E, Schneidman-Duhovny D, Andrusier N, Nussinov R, Wolfson HJ (2008) FireDock: a web server for fast interaction refinement in molecular docking. Nucleic Acids Res 36: W229-232.
38. Huang BX, Akbar M, Kevala K, Kim HY (2011) Phosphatidylserine is a critical modulator for Akt activation. J Cell Biol 192: 979-992.
39. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464. (Pubitemid 41637985)
40. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
41. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385: 399-408. (Pubitemid 40165072)
42. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, et al. (2005) Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4: 977-986. (Pubitemid 40909080)
43. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, et al. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59: 2551-2556. (Pubitemid 29269096)
44. Jetzt A, Howe JA, Horn MT, Maxwell E, Yin Z, et al. (2003) Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res 63: 6697-6706. (Pubitemid 37322949)
45. Davies MA, Lu Y, Sano T, Fang X, Tang P, et al. (1998) Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58: 5285-5290. (Pubitemid 28551100)